Please login to the form below

Not currently logged in
Email:
Password:

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).

Latest news

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... It currently has a second-line licence in Europe, but Ipsen

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics